Liver Disease Diagnostics

Liver Disease Diagnostics Market Outlook

The global Liver Disease Diagnostics Market is projected to reach USD 12.5 billion by 2035, growing at a CAGR of 6.2% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing prevalence of liver diseases, driven by rising alcohol consumption, obesity rates, and viral infections. Furthermore, advancements in diagnostic technologies and increased awareness about liver health are propelling the market forward. The demand for early diagnosis and effective treatment options for liver diseases has also amplified due to the growing burden of liver-related ailments. With a focus on enhancing healthcare infrastructure and improving access to diagnostic services, the market is set to experience significant growth in the coming years.

Growth Factor of the Market

The Liver Disease Diagnostics Market has been significantly influenced by a variety of growth factors. The rising incidence of liver diseases such as hepatitis and fatty liver disease has necessitated the development of reliable diagnostic methods, leading to increased investments in research and development. Moreover, the aging population is more susceptible to liver-related health issues, driving demand for more comprehensive diagnostic tests. Technological advancements, including the utilization of artificial intelligence in imaging techniques, have improved diagnostic accuracy and efficiency. Furthermore, government initiatives to promote awareness regarding liver disease prevention and treatment options are fostering market growth. Lastly, the increasing adoption of personalized medicine is expected to enhance the development of targeted liver disease diagnostics, further expanding the market.

Key Highlights of the Market

• The global liver disease diagnostics market is projected to reach USD 12.5 billion by 2035.
• Blood tests remain the most commonly used diagnostic method for liver diseases.
• Non-alcoholic fatty liver disease is expected to be the fastest-growing application segment.
• North America is anticipated to hold the largest market share due to the high prevalence of liver diseases.
• Technological advancements in imaging techniques such as MRI and CT scans are enhancing diagnostic accuracy.

By Test Type

Blood Tests:

Blood tests are a critical component of liver disease diagnostics, mainly because they allow for the assessment of liver function and detect liver inflammation or damage. Various blood tests, such as liver function tests (LFTs), measure enzymes, proteins, and substances produced or excreted by the liver. Elevated levels of enzymes like alanine aminotransferase (ALT) and aspartate aminotransferase (AST) can indicate liver damage, while tests for bilirubin and albumin help determine the liver's functional capacity. The convenience and non-invasive nature of blood tests contribute significantly to their widespread adoption, making them the primary choice for initial liver disease evaluation. As more healthcare providers emphasize routine screening, the demand for blood tests in liver diagnostics is expected to increase substantially.

Imaging Tests:

Imaging tests play a crucial role in diagnosing liver diseases by providing visualizations of the liver's structure and any abnormalities. Common imaging modalities include ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). Ultrasounds are often the first line of imaging due to their non-invasive nature and cost-effectiveness, enabling physicians to assess liver size, texture, and the presence of lesions or tumors. CT and MRI are utilized for more detailed evaluations, especially in complex cases such as liver cancer or cirrhosis. As technological advancements enhance imaging resolution and diagnostic capabilities, imaging tests are becoming integral in monitoring disease progression and treatment efficacy, leading to their increased usage in liver disease diagnostics.

Biopsy:

Liver biopsy remains the gold standard for diagnosing various liver disorders, particularly when assessing the extent of liver damage or determining the presence of fibrosis or cirrhosis. This invasive procedure involves removing a small tissue sample from the liver for histological examination. Although it provides precise information about liver pathology, its invasive nature and associated risks have led to the development of non-invasive alternatives, such as elastography. Despite this, liver biopsy is still widely used for definitive diagnosis, particularly in cases where non-invasive tests yield inconclusive results. The importance of liver biopsy in providing a comprehensive understanding of liver health ensures its continued relevance in the diagnostics market.

Elastography:

Elastography has emerged as a revolutionary non-invasive technique for assessing liver stiffness, which correlates with the degree of fibrosis or cirrhosis. This imaging modality uses ultrasound technology to evaluate liver elasticity, allowing clinicians to gauge the severity of liver disease without the need for a biopsy. The growing acceptance of elastography can be attributed to its ability to provide accurate and reproducible results, significantly reducing patient discomfort and associated risks. As awareness of liver disease management increases, elastography is anticipated to see substantial adoption, particularly in routine screenings and monitoring of chronic liver disease patients.

Endoscopy:

Endoscopy is utilized in liver disease diagnostics primarily for evaluating complications of liver disease, such as varices or portal hypertension. This procedure allows for direct visualization of the esophagus and stomach, helping to identify any lesions or bleeding complications associated with liver conditions. While not a primary diagnostic tool for liver diseases, it is essential for comprehensive management and treatment planning in advanced cases. The use of endoscopy in conjunction with other diagnostic methods ensures that clinicians can fully assess the impact of liver disease on the patient's overall health, making it a valuable component in the liver disease diagnostics landscape.

By End-user

Hospitals:

Hospitals are the primary end-users of liver disease diagnostics due to their comprehensive healthcare services and facilities. They are equipped with advanced diagnostic technologies and skilled professionals who can perform a wide range of tests, including blood tests, imaging, and biopsies. Hospitals also play a crucial role in managing patients with severe liver conditions, necessitating the availability of accurate diagnostic tools to guide treatment decisions. As the prevalence of liver diseases continues to rise, hospitals are increasingly investing in advanced diagnostic solutions to enhance patient care, thereby driving the growth of the liver disease diagnostics market.

Diagnostic Centers:

Diagnostic centers are specialized facilities dedicated to conducting various tests and analyses, making them a significant end-user in the liver disease diagnostics market. These centers often provide faster turnaround times for test results compared to hospitals, promoting early diagnosis and treatment initiation. The rise of standalone diagnostic centers has been fueled by the increasing demand for accessible healthcare services and the growing emphasis on preventive care. By offering a diverse range of diagnostic tests at competitive prices, these centers are not only improving access to liver disease diagnostics but are also contributing to the overall growth of the market.

Research Institutes:

Research institutes are instrumental in advancing liver disease diagnostics through innovation and clinical studies. They focus on developing new diagnostic tests and improving existing methodologies to enhance the accuracy and reliability of liver disease detection. Research institutes often collaborate with healthcare providers and pharmaceutical companies to explore novel diagnostic technologies, contributing to the evolution of personalized medicine in liver disease management. As they continue to explore the molecular and genetic underpinnings of liver diseases, research institutes will play an essential role in shaping the future landscape of liver disease diagnostics.

Others:

Other end-users, including home healthcare providers and telehealth services, are gradually entering the liver disease diagnostics market. With the advent of telemedicine, patients can now access diagnostic services remotely, which is particularly beneficial for those in rural or underserved areas. Home healthcare providers may utilize point-of-care testing and portable diagnostic devices to facilitate screening and monitoring of liver health. As the healthcare landscape evolves, the inclusion of various end-users in the liver disease diagnostics market is expected to enhance service accessibility and improve overall patient outcomes.

By Application

Alcoholic Liver Disease:

Alcoholic liver disease (ALD) is a significant application segment in the liver disease diagnostics market, driven by the rising consumption of alcoholic beverages globally. ALD encompasses various conditions, including alcoholic hepatitis and cirrhosis, necessitating accurate diagnostic tests for effective management and treatment. Diagnostic methods for ALD include liver function tests, imaging techniques, and liver biopsies to assess the extent of liver damage. The increasing awareness of the health risks associated with excessive alcohol consumption and the importance of early diagnosis are boosting the demand for diagnostic services tailored to ALD.

Non-alcoholic Fatty Liver Disease:

Non-alcoholic fatty liver disease (NAFLD) is emerging as one of the leading liver diseases globally, primarily due to the rising prevalence of obesity and metabolic disorders. NAFLD can progress to more severe liver conditions, making early diagnosis and monitoring crucial for effective management. A combination of blood tests and imaging studies is commonly employed to assess liver fat accumulation and inflammation. As healthcare providers prioritize preventive measures and lifestyle interventions for NAFLD management, the demand for accurate diagnostic solutions in this segment is expected to witness significant growth in the coming years.

Hepatitis:

Hepatitis, caused by viral infections, is a significant contributor to liver disease, necessitating widespread diagnostic testing to identify infected individuals. The hepatitis market segment includes diagnostics for hepatitis A, B, and C, with specific tests available for each type. Blood tests, including serological assays and polymerase chain reaction (PCR) tests, are integral in diagnosing and monitoring hepatitis infections. As vaccination programs and treatment options for hepatitis improve, the importance of early diagnosis and screening will continue to drive growth in this segment of the liver disease diagnostics market.

Liver Cancer:

Liver cancer is one of the most aggressive forms of cancer, and its timely diagnosis is paramount for improving patient outcomes. Diagnostic approaches for liver cancer often involve a combination of imaging tests, blood markers like alpha-fetoprotein (AFP), and biopsies to confirm the presence of malignancy. As awareness of liver cancer risks, particularly among high-risk populations, continues to grow, the demand for effective diagnostic solutions is increasing. Ongoing research efforts to identify novel biomarkers for early detection of liver cancer are likely to further enhance the diagnostic capabilities available in this application segment.

By Technology

PCR:

Polymerase chain reaction (PCR) technology has revolutionized the field of diagnostics, particularly in the detection of viral hepatitis infections. This molecular technique allows for the amplification of specific DNA or RNA sequences, facilitating the identification of viral genomes in blood samples. PCR is highly sensitive and specific, making it a valuable tool for diagnosing hepatitis B and C infections. As research in molecular diagnostics continues to advance, the adoption of PCR technology in liver disease diagnostics is expected to expand, particularly for patient monitoring and treatment response assessment.

ELISA:

Enzyme-linked immunosorbent assay (ELISA) is widely used for the serological diagnosis of liver diseases, particularly for viral hepatitis and autoimmune liver disorders. This immunological technique detects specific antibodies or antigens in the patient's blood, providing valuable information about the presence of liver infections or conditions. The high throughput nature of ELISA makes it suitable for large-scale screening programs, contributing to its popularity in clinical laboratories. As the prevalence of liver diseases continues to rise, the demand for ELISA-based diagnostics is expected to grow, driven by the need for effective screening and diagnosis.

MRI:

Magnetic resonance imaging (MRI) stands as a powerful imaging technology for diagnosing liver diseases, providing detailed cross-sectional images of the liver and surrounding structures. MRI is particularly useful for assessing liver tumors, lesions, and fibrosis, offering superior soft tissue contrast compared to other imaging modalities. As advancements in MRI technology, such as functional MRI and diffusion-weighted imaging, enhance diagnostic accuracy, the adoption of MRI in liver diagnostics is expected to increase significantly. The non-invasive nature of MRI, coupled with its ability to provide comprehensive liver assessments, makes it an essential tool in the diagnostics market.

Ultrasound:

Ultrasound is often the first-line imaging modality for evaluating liver diseases due to its non-invasive and cost-effective nature. It allows for real-time visualization of the liver, facilitating the detection of abnormalities such as cysts, tumors, and fatty liver. The growing prevalence of chronic liver diseases and the need for routine screening are driving the demand for ultrasound diagnostics. Moreover, the introduction of advanced ultrasound techniques, such as elastography, has further expanded the scope of ultrasound in liver disease diagnostics. As healthcare providers emphasize early detection and management, the use of ultrasound is likely to remain a cornerstone in this market.

CT Scan:

Computed tomography (CT) scan is a crucial imaging technique utilized in liver disease diagnostics, particularly for assessing liver tumors and complex cases. CT scans provide detailed cross-sectional images, enabling physicians to visualize liver structure and identify any lesions or masses accurately. The speed of CT imaging makes it an excellent choice for emergency scenarios where rapid diagnosis is essential. Additionally, advancements in CT technology, such as dual-energy CT and high-resolution imaging, are enhancing its diagnostic capabilities. As the demand for accurate and timely liver disease diagnostics increases, CT scans will continue to play a vital role in clinical practice.

By Region

The liver disease diagnostics market is experiencing varying growth rates across different regions, with North America expected to dominate the landscape. The North American market is projected to grow at a CAGR of 6.5%, driven by the high prevalence of liver diseases such as hepatitis and alcoholic liver disease. The advanced healthcare infrastructure, coupled with a strong focus on research and development, is facilitating the adoption of innovative diagnostic technologies. Furthermore, increasing awareness about liver health and the availability of comprehensive treatment options contribute to the region's market growth.

In Europe, the liver disease diagnostics market is also gaining momentum, fueled by a rising incidence of non-alcoholic fatty liver disease and hepatitis infections. The European market is expected to witness steady growth, supported by government initiatives aimed at promoting awareness and screening programs. Meanwhile, the Asia Pacific region is emerging as a significant market, driven by a large population base and increasing healthcare expenditures. As more countries in Asia enhance their healthcare infrastructure and access to diagnostic services, the demand for liver disease diagnostics is anticipated to rise, further contributing to the global market dynamics. The overall regional analysis indicates that while North America leads in market share, other regions are rapidly evolving and expanding their diagnostics capabilities.

Opportunities

The Liver Disease Diagnostics Market holds numerous opportunities for growth, particularly in the realm of technological advancements. The integration of artificial intelligence (AI) and machine learning in diagnostic tools is poised to enhance the accuracy and efficiency of liver disease detection. AI algorithms can analyze imaging data and clinical information to assist healthcare providers in making informed decisions and predicting disease progression. As research in this area grows, companies that invest in AI-driven diagnostic solutions will likely gain a competitive edge, offering innovative products that meet the evolving needs of the healthcare market. Furthermore, the move towards personalized medicine presents a unique opportunity for diagnostic companies to develop tailored solutions that cater to individual patient profiles, thereby improving outcomes and patient satisfaction.

Another significant opportunity lies in the increasing emphasis on preventive healthcare and early diagnosis. Governments and health organizations worldwide are prioritizing initiatives aimed at educating the public about liver health and the importance of routine screenings. This focus on early detection is driving demand for accessible and efficient diagnostic solutions across diverse healthcare settings. Additionally, as the prevalence of liver diseases continues to rise, there is a pressing need for cost-effective diagnostic alternatives that can be implemented in various healthcare environments. Companies that can develop and market affordable diagnostic tests will be well-positioned to capture significant market share and contribute to improving global liver health outcomes.

Threats

Despite the promising growth trajectory of the liver disease diagnostics market, several threats may pose challenges to its advancement. One of the primary threats is the increasing competition among diagnostic manufacturers, leading to price pressures and market saturation. As more players enter the market with innovative solutions, established companies may find it challenging to maintain their market share and profitability. This competitive landscape could result in price wars, undermining the financial stability of smaller companies that lack the resources to withstand such challenges. Additionally, the rapid pace of technological advancements may lead to obsolescence, requiring continuous investment in research and development to stay relevant in the market.

Another threat to the liver disease diagnostics market is the regulatory environment that governs medical diagnostic tools. Stringent regulatory requirements can slow down the approval process for new diagnostic technologies, delaying their entry into the market. Manufacturers must navigate complex regulatory landscapes to ensure compliance, which can be resource-intensive and time-consuming. Moreover, any changes in regulations may impact the availability and accessibility of diagnostic tests, affecting healthcare providers and patients alike. Companies that cannot adapt to evolving regulatory demands may face significant setbacks, hindering their growth potential within the market.

Competitor Outlook

• Abbott Laboratories
• Roche Diagnostics
• Thermo Fisher Scientific
• Siemens Healthineers
• GE Healthcare
• Philips Healthcare
• Becton, Dickinson and Company
• BioMérieux
• PerkinElmer
• Hologic, Inc.
• Carestream Health
• Ortho Clinical Diagnostics
• DiaSorin S.p.A.
• Canon Medical Systems Corporation
• Mindray Medical International Limited

The competitive landscape of the liver disease diagnostics market is characterized by the presence of both established companies and emerging players. The key players are focusing on innovation and technological advancements to enhance their diagnostic offerings and gain a competitive edge. Companies like Abbott Laboratories and Roche Diagnostics have a strong foothold in the market, providing a wide range of diagnostic tests and technologies. They are investing heavily in research and development to introduce next-generation diagnostic solutions that cater to the evolving needs of healthcare providers and patients. Additionally, strategic partnerships and collaborations among industry players are becoming increasingly common, aimed at leveraging complementary strengths and expanding market reach.

Emerging companies are also making significant strides in the liver disease diagnostics market, often focusing on niche technologies and specialized products. For instance, companies specializing in molecular diagnostics, such as Thermo Fisher Scientific, are developing innovative solutions that enhance the detection of viral hepatitis using advanced PCR techniques. The growing trend of personalized medicine is spurring investment in companies that can offer tailored diagnostic tests based on individual patient profiles. As the healthcare landscape shifts towards precision medicine, the collaboration between diagnostic manufacturers and research institutes is likely to foster innovation and drive growth in the liver disease diagnostics market.

In conclusion, the liver disease diagnostics market is poised for significant growth, driven by rising disease prevalence, technological advancements, and increasing awareness about liver health. Competition is expected to intensify as established players and emerging companies strive to differentiate their products and capture market share. Effective collaboration between industry stakeholders, including healthcare providers, research institutions, and diagnostic manufacturers, will be essential to address the challenges and harness the opportunities present in this dynamic market. With a strong focus on innovation and patient-centric solutions, the future of liver disease diagnostics looks promising, ultimately improving patient outcomes and quality of care.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 PerkinElmer
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 GE Healthcare
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Hologic, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 DiaSorin S.p.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 BioMérieux
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Carestream Health
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Diagnostics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Philips Healthcare
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Abbott Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Thermo Fisher Scientific
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Ortho Clinical Diagnostics
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Becton, Dickinson and Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Canon Medical Systems Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Mindray Medical International Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Liver Disease Diagnostics Market, By user
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Centers
    • 6.1.3 Research Institutes
    • 6.1.4 Others
  • 6.2 Liver Disease Diagnostics Market, By Test Type
    • 6.2.1 Blood Tests
    • 6.2.2 Imaging Tests
    • 6.2.3 Biopsy
    • 6.2.4 Elastography
    • 6.2.5 Endoscopy
  • 6.3 Liver Disease Diagnostics Market, By Application
    • 6.3.1 Alcoholic Liver Disease
    • 6.3.2 Non-alcoholic Fatty Liver Disease
    • 6.3.3 Hepatitis
    • 6.3.4 Liver Cancer

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Liver Disease Diagnostics Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Liver Disease Diagnostics market is categorized based on

By Test Type

• Blood Tests
• Imaging Tests
• Biopsy
• Elastography
• Endoscopy

By user

• Hospitals
• Diagnostic Centers
• Research Institutes
• Others

By Application

• Alcoholic Liver Disease
• Non-alcoholic Fatty Liver Disease
• Hepatitis
• Liver Cancer

By Region

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Abbott Laboratories
• Roche Diagnostics
• Thermo Fisher Scientific
• Siemens Healthineers
• GE Healthcare
• Philips Healthcare
• Becton, Dickinson and Company
• BioMérieux
• PerkinElmer
• Hologic, Inc.
• Carestream Health
• Ortho Clinical Diagnostics
• DiaSorin S.p.A.
• Canon Medical Systems Corporation
• Mindray Medical International Limited